Rubicon Research Limited
ListedMainboardHealthcare · NSE / BSE
Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company focused on developing, manufacturing, and commercializing differentiated formulations. As of June 30, 2025, it has 72 US FDA-approved ANDA and NDA products, with 66 commercialized in a US generic market worth USD 2,455.7 million, contributing USD 195 million in Fiscal 2024. The company has 17 products awaiting US FDA approval and 63 in development, marketing over 350 SKUs to 96 customers, including major wholesalers, pharmacy chains, GPOs, and managed care organizations. Globally, Rubicon has registered or filed 48 products across Australia, the UK, Singapore, Saudi Arabia, and the UAE, planning commercial launch upon approval, and offers contract manufacturing in India, Australia, and New Zealand. Its operations include three manufacturing facilities in India and two US FDA-inspected R&D centers in India and Canada.
Price Band
₹461 – ₹485
Issue Size
₹1378 Cr
Lot Size
30 shares
GMP
₹120
+24.7%
Est. Listing
₹605
at current GMP
Subscribed
109.33x
overall
Open
9 Oct 2025
Close
13 Oct 2025
Allotment
14 Oct 2025
Refund
15 Oct 2025
Demat Credit
16 Oct 2025
Listing
16 Oct 2025
Last updated 12 days ago
Official Registrar Verification
Rubicon Research Limited Allotment Status
Designated Registrar: Link Intime India Private Ltd (MUFG)
Allotment Date
14 Oct 2025
Basis finalization
Refunds Initiate
15 Oct 2025
Mandate release
Demat Credit
16 Oct 2025
Shares in demat
Listing Debut
16 Oct 2025
Trading begins
How to Check Rubicon Research Limited IPO Allotment Status
- Click the Check on Registrar button above to visit Link Intime India Private Ltd (MUFG)'s allotment portal.
- Select Rubicon Research Limited from the dropdown company list.
- Choose your lookup mode: PAN Number, Application Number, or DP Client ID.
- Enter your details accurately and solve the Captcha code.
- Click Submit / Search to view the number of shares applied and allotted to you.
About Rubicon Research Limited Public Issue & Market Profile
Rubicon Research Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,377.5 Crores. The shares are offered at a price band of ₹461 to ₹485 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Public Issue & Allotment Procedure:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 30 shares (approx. ₹14,550 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Official Allotment Timelines & Registrar Guidance:
Allotment reconciliation will be managed by Link Intime India Private Ltd (MUFG). Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-10-16, while un-allotted funds or UPI block mandates will be released on 2025-10-15.
Frequently Asked Questions
What if my name is not showing on the registrar portal?
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
How will I receive the refund if I don't get allotment?
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.